Physician profile
George Hsu
NPI 1881801157
$3,592.46
in general payments reported to CMS, 2019-2025
14 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $1,470 · 2021: $174 · 2022: $434 · 2023: $395 · 2024: $507 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,259.30 |
| Education | $123.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,682.73 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $641.01 | 2019-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $268.35 | 2024 | Voquezna |
| Genzyme Corporation | $213.82 | 2019-2025 | |
| Inspire Medical Systems, INC. | $165.12 | 2023-2025 | Inspire |
| Aerin Medical INC. | $151.59 | 2022-2025 | |
| Stryker Corporation | $138.98 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $89.00 | 2025 | |
| Abbvie INC. | $67.57 | 2024-2025 | |
| Acclarent, INC | $61.56 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $38.90 | 2025 | Tezspire |
| Amgen INC. | $34.00 | 2025 | |
| Smith+Nephew, INC. | $24.88 | 2022 | |
| Optinose US, INC. | $14.95 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.